Table 2. Preoperative anti-glaucoma medication.
| Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4 | Total | |
|---|---|---|---|---|---|
| 6.75 μg | 22.5 μg | 67.5 μg | 225 μg | ||
| (0.3 μM) | (1 μM) | (3 μM) | (10 μM) | ||
| N = 3 (100%) | N = 3 (100%) | N = 3 (100%) | N = 3 (100%) | N = 12 (100%) | |
| Number of preoperative anti-glaucoma medication componentsa | 3 (100) 10 | 3 (100) 12 | 3 (100) 10 | 3 (100) 8 | 12 (100) 40 |
| Meanb | 3.3 | 4.0 | 3.3 | 2.7 | 3.3 |
| SD | 1.15 | 0.00 | 0.58 | 0.58 | 0.78 |
| Rangec | 2–4 | 4–4 | 3–4 | 2–3 | 2–4 |
| Drug classa | |||||
| β-blocking agents | 2 (66.7) 2 | 3 (100) 3 | 3 (100) 3 | 2 (66.7) 2 | 10 (83.3) 10 |
| Carbonic anhydrase inhibitors | 3 (100) 3 | 3 (100) 3 | 1 (33.3) 1 | 3 (100) 3 | 10 (83.3) 10 |
| Prostaglandin analogues | 2 (66.7) 2 | 3 (100) 3 | 3 (100) 3 | 2 (66.7) 2 | 10 (83.3) 10 |
| Adrenergic agonists | 3 (100) 3 | 3 (100) 3 | 3 (100) 3 | 1 (33.3) 1 | 10 (83.3) 10 |
anumbers indicate patients per dose level receiving medication (percentage of patients) total number of anti-glaucoma medication components/substances
bMean: total number of preoperative anti-glaucoma medication components/number of patients receiving preoperative anti-glaucoma medication
cRange: lowest and highest number of preoperative anti-glaucoma medication components for patients in this dose group